Targeting CD4+ Cells to Treat Ischemia Reperfusion Injury

There is currently no specific therapy for ischemic acute renal failure. We have recently identified that CD4+ T cells directly participate in the pathogenesis of the injury. Furthermore, modulating CD4+ T cells improves the course of ischemic acute renal failure. With rapid developments in immunology that are now allowing for modulation of CD4+ cell function, these results have opened a new opportunity for patients with ischemic acute renal failure. Furthermore, this approach is likely to be successful in ischemic injury to other organs, such as heart, brain and intestine. Description (Set) Proposed Use (Set) Ischemic injury to the kidney occurs during cadaveric organ transplantation. This limits the number of organs that can be used, and leads to significant problems in patients who receive transported, ischemic kidneys. Furthermore, ischemic injury to the native kidney is the leading cause of nephrology consultations in a tertiary hospital setting. Thus, these two common disease entities are ripe for application of this concept. In addition, ischemic injury to the heart is seen after myocardial ischemia, brain ischemia during stroke, and intestinal ischemia during hypotension. All these are potentially amenable to this novel therapeutic approach and constitute a large
Patent (Set) WO 03/024399

Patents:
US 3,024,399

Inventor(s): Rabb, Hamid

Type of Offer: Licensing



« More Medical Patents

---